Leong Natalie Ee Mun 4

What Happened

• Natalie Ee Mun Leong, a director of Quoin Pharmaceuticals, was granted a derivative award on Feb 4, 2026 covering 12,211 ADSs. The filing shows $0.00 paid at grant (no cash exchanged at issuance). Per the filing, each ADS represents 35 ordinary shares, so the award equals 427,385 ordinary shares on an ADS-equivalent basis. This is a time‑based award (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (appears timely under the two-business‑day reporting rule).
• Transaction type: A = Award/Grant of a derivative security (option/award reported in ADS terms).
• Amount: 12,211 ADSs granted (equals 427,385 ordinary shares).
• Price at grant: $0.00 recorded (no cash paid at grant).
• Vesting (per footnote): 20% vests Feb 4 each year 2027, 2028 and 2029; 40% vests Feb 4, 2030.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes: F1 clarifies counts/exercise price are reported in ADSs (1 ADS = 35 ordinary shares); F2 provides the four-year vesting schedule.

Context

• This is a time‑based director award intended for retention/compensation; it does not represent an immediate market purchase or sale. The award vests over four years, so it provides future equity exposure rather than current stock ownership. Awards to directors are common and do not by themselves indicate an immediate trading intent.